Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Terminated 4Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 5Renal Insufficiency 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Multiple Myeloma × melflufen × Clear all
NCT03151811 2024-01-30

OCEAN

Oncopeptides AB

Phase 3 Terminated
495 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT04649060 2023-06-08

LIGHTHOUSE

Oncopeptides AB

Phase 3 Terminated
54 enrolled 21 charts
Plasma cell

Multiple Myeloma

NCT03639610 2023-03-10

BRIDGE

Oncopeptides AB

Phase 2 Terminated
35 enrolled 33 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT03481556 2022-12-19

ANCHOR

Oncopeptides AB

Phase 1/2 Terminated
56 enrolled 22 charts
Plasma cell

Multiple Myeloma

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed
157 enrolled 26 charts 1 FDA
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡